ASCO18: Trial shows how PET scans help tailor therapy for esophageal cancer
Share

IMAGE: At ASCO 18, Karyn Goodman, MD, MS, reports results of CALGB 80303 trial showing that PET scan after induction chemotherapy can show which esophageal cancer patients should maintain/switch regimens. view more 

Credit: University of Colorado Cancer Center

Survival results for the CALGB 80303 Trial presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 demonstrate that esophageal cancer patients shown by PET scan to be non-responders to induction chemotherapy, and were then switched to a new chemotherapy during chemoradiation, showed median overall survival of 27 months. This improves on 18-month median overall survival of previous studies that used the same chemotherapy with non-responders during induction and chemoradiation treatment phases. Patients who were shown by PET to be responders to induction chemotherapy with the regimen FOLFOX and then stayed on FOLFOX during chemoradiation showed 55 percent 4-year survival, the best ever outcome reported for patients with this disease.

“Esophageal cancer patients undergo treatments to shrink tumors before surgery. We wanted to see if PET scan could help us personalize the best pre-operative treatment,” says Karyn Goodman, MD, MS, Grohne Chair of Clinical Oncology at University of Colorado Cancer Center, and the national study chair of the

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD